Loading patent…
AssigneeNOXXON Pharma AG
InventorsWerner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
Estimating the term…
The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
A method for the treatment of a subject suffering from cancer, wherein the method comprises a) administering to the subject a pharmaceutically effective amount of a type B L-nucleic acid, or a homolog thereof, that binds SDF-1, wherein said type B L-nucleic acid comprises, in order, a 5′ flanking sequence, SEQ ID NO:52 and a 3′ flanking sequence, wherein said 5′ and 3′ flanking sequences can hybridize to each other.
Dependencies are inferred from the claim text.